See every side of every news story
Published loading...Updated

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

  • The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
  • Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
  • Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.
Insights by Ground AI
Does this summary seem wrong?

162 Articles

All
Left
35
Center
86
Right
16
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 63% of the sources are Center
63% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Star Advertiser broke the news in Honolulu, United States on Friday, December 8, 2023.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.